Construction of a Prognostic Prediction Model in Liver Cancer Based on Genes Involved in Integrin Cell Surface Interactions Pathway by Multi-omics Screening

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2024 Feb 20

PMID 38374893

Authors

Xiang Yu

Hao Zhang

Jinze Li

Lu Gu

Lei Cao

Jun Gong

Ping Xie

Jian Xu

Affiliations

Soon will be listed here.

Abstract

Liver cancer is a common malignant tumor with an increasing incidence in recent years. We aimed to develop a model by integrating clinical information and multi-omics profiles of genes to predict survival of patients with liver cancer. The multi-omics data were integrated to identify liver cancer survival-associated signal pathways. Then, a prognostic risk score model was established based on key genes in a specific pathway, followed by the analysis of the relationship between the risk score and clinical features as well as molecular and immunologic characterization of the key genes included in the prediction model. The function experiments were performed to further elucidate the undergoing molecular mechanism. Totally, 4 pathways associated with liver cancer patients' survival were identified. In the pathway of integrin cell surface interactions, low expression of COMP and SPP1, and low CNVs level of COL4A2 and ITGAV were significantly related to prognosis. Based on above 4 genes, the risk score model for prognosis was established. Risk score, ITGAV and SPP1 were the most significantly positively related to activated dendritic cell. COL4A2 and COMP were the most significantly positively associated with Type 1 T helper cell and regulatory T cell, respectively. The nomogram (involved T stage and risk score) may better predict short-term survival. The cell assay showed that overexpression of ITGAV promoted tumorigenesis. The risk score model constructed with four genes (COMP, SPP1, COL4A2, and ITGAV) may be used to predict survival in liver cancer patients.

References

Chen W, Chang Y, Hsu H, Yen M, Huang H, Cho C . Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer. Oncotarget. 2015; 6(40):42923-37. PMC: 4767481. DOI: 10.18632/oncotarget.5976. View

Wu W, Dang S, Feng Q, Liang J, Wang Y, Fan N . MicroRNA-542-3p inhibits the growth of hepatocellular carcinoma cells by targeting FZD7/Wnt signaling pathway. Biochem Biophys Res Commun. 2016; 482(1):100-105. DOI: 10.1016/j.bbrc.2016.10.136. View

McLaren W, Gil L, Hunt S, Riat H, Ritchie G, Thormann A . The Ensembl Variant Effect Predictor. Genome Biol. 2016; 17(1):122. PMC: 4893825. DOI: 10.1186/s13059-016-0974-4. View

Farazi P, DePinho R . Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006; 6(9):674-87. DOI: 10.1038/nrc1934. View

Gao Q, Qiu S, Fan J, Zhou J, Wang X, Xiao Y . Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007; 25(18):2586-93. DOI: 10.1200/JCO.2006.09.4565. View

Thiery J, Acloque H, Huang R, Nieto M . Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5):871-90. DOI: 10.1016/j.cell.2009.11.007. View

Long J, Chen P, Lin J, Bai Y, Yang X, Bian J . DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Theranostics. 2019; 9(24):7251-7267. PMC: 6831284. DOI: 10.7150/thno.31155. View

Lugano R, Vemuri K, Yu D, Bergqvist M, Smits A, Essand M . CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis. J Clin Invest. 2018; 128(8):3280-3297. PMC: 6063507. DOI: 10.1172/JCI97459. View

Lightbody G, Haberland V, Browne F, Taggart L, Zheng H, Parkes E . Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application. Brief Bioinform. 2018; 20(5):1795-1811. PMC: 6917217. DOI: 10.1093/bib/bby051. View

10.

Stupp R, Hegi M, Gorlia T, Erridge S, Perry J, Hong Y . Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(10):1100-8. DOI: 10.1016/S1470-2045(14)70379-1. View

11.

Sircana A, Paschetta E, Saba F, Molinaro F, Musso G . Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma. Int J Mol Sci. 2019; 20(7). PMC: 6480228. DOI: 10.3390/ijms20071745. View

12.

Cheuk I, Siu M, Ho J, Chen J, Shin V, Kwong A . targeting as a therapeutic approach for treatment of metastatic breast cancer. Am J Cancer Res. 2020; 10(1):211-223. PMC: 7017729. View

13.

Shen X, Li N, Li H, Zhang T, Wang F, Li Q . Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010; 136(11):1745-54. DOI: 10.1007/s00432-010-0833-8. View

14.

Liu Z, Chang Q, Yang F, Liu B, Yao H, Bai Z . Long non-coding RNA NEAT1 overexpression is associated with unfavorable prognosis in patients with hepatocellular carcinoma after hepatectomy: A Chinese population-based study. Eur J Surg Oncol. 2017; 43(9):1697-1703. DOI: 10.1016/j.ejso.2017.06.013. View

15.

Speicher T, Siegenthaler B, Bogorad R, Ruppert R, Petzold T, Padrissa-Altes S . Knockdown and knockout of β1-integrin in hepatocytes impairs liver regeneration through inhibition of growth factor signalling. Nat Commun. 2014; 5:3862. DOI: 10.1038/ncomms4862. View

16.

Werner H, Mills G, Ram P . Cancer Systems Biology: a peek into the future of patient care?. Nat Rev Clin Oncol. 2014; 11(3):167-76. PMC: 4321721. DOI: 10.1038/nrclinonc.2014.6. View

17.

Yung M, Lo K, Yip C, Chung G, Tong C, Cheung P . Copy number gain of granulin-epithelin precursor (GEP) at chromosome 17q21 associates with overexpression in human liver cancer. BMC Cancer. 2015; 15:264. PMC: 4403714. DOI: 10.1186/s12885-015-1294-x. View

18.

Wang L, Sun L, Liu R, Mo H, Niu Y, Chen T . Long non-coding RNA MAPKAPK5-AS1/PLAGL2/HIF-1α signaling loop promotes hepatocellular carcinoma progression. J Exp Clin Cancer Res. 2021; 40(1):72. PMC: 7891009. DOI: 10.1186/s13046-021-01868-z. View

19.

Takata Y, Nakamoto Y, Nakada A, Terashima T, Arihara F, Kitahara M . Frequency of CD45RO+ subset in CD4+CD25(high) regulatory T cells associated with progression of hepatocellular carcinoma. Cancer Lett. 2011; 307(2):165-73. DOI: 10.1016/j.canlet.2011.03.029. View

20.

Fan X, Guo H, Dai B, He L, Zhou D, Lin H . The association between methylation patterns of DNAH17 and clinicopathological factors in hepatocellular carcinoma. Cancer Med. 2018; 8(1):337-350. PMC: 6346260. DOI: 10.1002/cam4.1930. View